CaronAlyceJacobsonMD

PubMed

• Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
  Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Armin Ghobadi, Sairah Ahmed, David B Miklos, Miguel-Angel Perales, Javier Munoz, Warren B Fingrut, Martina Pennisi,...> ;Blood. 2024 Apr 18
• Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States.
  Markqayne D Ray, Katherine L Rosettie, Graeme Ball, Jorge Jacob, S Pinar Bilir, Anik R Patel, Olalekan O Oluwole, Caron A Jacobson> ;Value in Health. 2024 Apr 17
• Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
  Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy, Carr...> ;Journal of Clinical Oncology. 2024 Mar 29
• Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-ce...
  Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sairah Ahmed, David B Miklos, Yi Lin, Brian T Hill, Armin Ghobadi, S...> ;American Journal of Hematology. 2024 May 1
• Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
  Nemec, R., Scherrer-Crosbie, M., Abramson, J., Redd, R., Gilman, H., Ho, T., Wu, J., Heemelaar, J., Neuberg, D., Hochberg, E., Barnes, J., Armand, P., Jacobsen, E., Ja...> ;Leukemia & Lymphoma. 2024 Feb 21
• 3 citations
  Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
  Epperla, N., Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew Ulrickson, Emmanuel Bachy, Pashna N Munshi, Carla Casulo, David G Maloney...> ;Blood. 2024 Feb 8
• Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
  Ghobadi, A., Munoz, J., Westin, J., Locke, F., Miklos, D., Rapoport, A., Perales, M., Reagan, P., McGuirk, J., Jacobson, C., Kersten, M., Avivi, I., Peng, A., Schupp, ...> ;Blood Advances. 2024 Feb 5
• A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
  Paola Ghione, M Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Jessica Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S Ne...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 May 1
• Checkpoints: roadblocks or repairs for the CAR-T journey?
  Crombie, J., Jacobson, C.> ;Blood Advances. 2024 Jan 23
• Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
  Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Ke...> ;Bone Marrow Transplantation. 2024 Mar 1
• Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
  Ahn, I., Brander, D., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C., Armand, P., Ng, S., C...> ;Blood Advances. 2024 Feb 27
• Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...
  Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
• 1 citations
  Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023.
  Ryan, C., Jacobson, C.> ;Seminars in Hematology. 2023 Nov 1
• 1 citations
  Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
  Amar H Kelkar, Edward R Scheffer Cliff, Caron A Jacobson, Gregory A Abel, Stijntje W Dijk, Eline M Krijkamp, Robert Redd, Joanna C Zurko, Mehdi Hamadani, M G Myriam Hu...> ;Annals of Internal Medicine. 2023 Dec 1
• Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
  Caron A Jacobson, Javier Munoz, Fang Sun, Steve Kanters, Eve H Limbrick-Oldfield, Clare Spooner, Krystal Mignone, Francis Ayuk, Robin Sanderson, James Whitmore, Yuanyu...> ;Transplantation and Cellular Therapy. 2024 Jan 1
• A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
  Reid W Merryman, Robert A Redd, Arnold S Freedman, Inhye E Ahn, Jennifer R Brown, Jennifer L Crombie, Matthew S Davids, David C Fisher, Eric D Jacobsen, Austin I Kim, ...> ;Annals of Hematology. 2024 Jan 1
• 1 citations
  A road map for navigating CAR T hematotoxicity.
  David Qualls, Caron Jacobson> ;Blood. 2023 Sep 7
• 1 citations
  Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.
  Parth S Shah, Caron A Jacobson> ;Hematology/oncology Clinics of North America. 2023 Dec 1
• 3 citations
  Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
  Christine E Ryan, Rebecca L Zon, Robert Redd, David C Fisher, Roni Shouval, Anita Kumar, Jennifer L Crombie, Hossein Sadrzadeh, Austin I Kim, Lakshmi Nayak, Ugonma N C...> ;British Journal of Haematology. 2023 Dec 1
• CAR T Cells: Past Successes, Current Limitations, and Future Opportunities.
  Parth S Shah, Caron A Jacobson> ;Hematology/oncology Clinics of North America. 2023 Dec 1
• 19 citations
  Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
  Tomas G Neilan, Thiago Quinaglia, Takeshi Onoue, Syed S Mahmood, Zsofia D Drobni, Hannah K Gilman, Amanda Smith, Julius C Heemelaar, Priya Brahmbhatt, Jor Sam Ho, Supr...> ;JAMA. 2023 Aug 8
• Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG.
  Christine A Eckhardt, Haoqi Sun, Preeti Malik, Syed Quadri, Marcos Santana Firme, Daniel K Jones, Meike van Sleuwen, Aayushee Jain, Ziwei Fan, Jin Jing, Wendong Ge, Hu...> ;Annals of Clinical and Translational Neurology. 2023 Oct 1
• 1 citations
  Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.
  Michael D Jain, David B Miklos, Caron A Jacobson, John M Timmerman, Jennifer Sun, Jenny Nater, Xiang Fang, Ankit Patel, Madison Davis, Darren Heeke, Tan Trinh, Mike Ma...> ;Clinical Cancer Research. 2023 Oct 13
• 1 citations
  Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
  David Qualls, Caron A Jacobson> ;Blood Advances. 2023 Jul 25
• 4 citations
  A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.
  Caron A Jacobson, Allison C Rosenthal, Jon Arnason, Shirali Agarwal, Peixin Zhang, Wendy Wu, Vian Amber, Jean A Yared> ;Blood Advances. 2023 Nov 14
• Join now to see all

Journal Articles

• Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-cell Therapy  
  Sarah Nikiforow, Caron Jacobson, JAMA Neurology

Abstracts/Posters

• ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma
  Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
  Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
  Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...
  Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
  Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
  Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Adult Clinical Malignant Hematology 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Indolent Lymphomas: The Marathon Has a New Course 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all